Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Dual complement and P-selectin inhibitor, IHP-102, prevents lung vaso-occlusion in P-selectin-deficient townes SS mice

John Paderi, Rikesh Dubey, Tomasz Kaminski et al. Nov 03, 2025 pp. 4707-4707 10.1182/blood-2025-4707

Abstract Background Sickle cell disease (SCD) is the most common monogenic blood disorder that is widely recognized for its hallmark vaso-oc...

Nationwide impact of CAR-T approval on acute lymphoblastic leukemia mortality in the United States, 1999-2023: Difference-in-differences and synthetic control analyses

Woo Joo Lee, Muhammad Sohaib Asghar, Seon Hye Won et al. Nov 03, 2025 pp. 4535-4535 10.1182/blood-2025-4535

Abstract Background Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy received its first U.S. approval for rela...

Incidence and risk factors of Epstein–Barr virus reactivation and post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: A 985-patient retrospective cohort analysis

Fei Gao, Xinyu Wang, Yi Luo et al. Nov 03, 2025 pp. 4280-4280 10.1182/blood-2025-4280

Abstract Background: Epstein-Barr Virus (EBV) reactivation frequently occurs following allogenic stem cell transplantation (allo-HSCT). In a...

Hnrnpk haploinsufficiency in del(9q) Acute Myeloid Leukemia reveals targetable vulnerabilities

Sean Post, Oscar Benitez, Ashley Rodriguez et al. Nov 03, 2025 pp. 5028-5028 10.1182/blood-2025-5028

Abstract Deletion of the long arm of chromosome 9, del(9q), is a recurrent cytogenetic abnormality in AML and encompasses the HNRNPK locus a...

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

Darren Pan, Eric Chinaeke, Yi-Hsuan Liu et al. Nov 03, 2025 pp. 2818-2818 10.1182/blood-2025-2818

Abstract Introduction Multiple myeloma (MM), the second most common hematologic cancer, is estimated to have 36,110 new United States (US) c...

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Jennifer Brown, Swetha Challagulla, David Campbell et al. Nov 03, 2025 pp. 7443-7443 10.1182/blood-2025-7443

Abstract Introduction Efficacy of the Bruton tyrosine kinase inhibitors zanubrutinib and ibrutinib as first-line (1L) tr...

Pre-diagnostic biomarkers show disease susceptibility continuum and enable early prediction of multiple myeloma

Jiadai Xu, Bingjie Li, Zhigang Yao et al. Nov 03, 2025 pp. 2231-2231 10.1182/blood-2025-2231

Abstract Background At diagnosis, multiple myeloma (MM) typically presents with a constellation of clinical features, including anemia, rena...

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Yuichi Ishikawa, Takahiro Yamauchi, Masashi Sawa et al. Nov 03, 2025 pp. 998-998 10.1182/blood-2025-998

Abstract Introduction: The prognosis of newly diagnosed FLT3-mutated adult acute myeloid leukemia (AML) has recently improved by the combina...

Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia

Li-Ping Yang, Hai-Xia Fu, Mengtong Zang et al. Nov 03, 2025 pp. 1271-1271 10.1182/blood-2025-1271

Abstract IntroductionPrimary immune thrombocytopenia (ITP) is an autoimmune disease, posing a serious threat to human health as one of the m...

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Jian Huang, Tian Zeng, Xiudi Yang et al. Nov 03, 2025 pp. 2034-2034 10.1182/blood-2025-2034

Abstract Introduction: Overexpression of anti-apoptotic proteins BCL-2 and BCL-XL has been observed in tumor cells of myelofibrosis (MF) pat...

primary thromboprophylaxis using direct oral anti-coagulants (DOAC) in malignant pediatric tumors with vascular compression

Max Cohen, Gillian Graifman, Zainab Zulqarnain et al. Nov 03, 2025 pp. 4899-4899 10.1182/blood-2025-4899

Abstract INTRODUCTION Cancer-associated thrombosis (CAT) is a recognized complication of pediatric malignancies. Vascular compression increas...

Diagnostic spectrum of CD5-positive, CD23-negative B-cell lymphoproliferative disorders: Analysis of a two-year patient cohort

Gohar Tadevosyan, Lilit Matinyan, Gevorg Saghumyan et al. Nov 03, 2025 pp. 7428-7428 10.1182/blood-2025-7428

Abstract Introduction: Chronic B-cell lymphoproliferative disorders (B-CLPDs) comprise a heterogeneous group of malignancies involving the c...

IRF2BP2 mutations activate IL-1β-mediated NF-κB signaling and confer actionable anti-IL-1β sensitivity in DLBCL

Areya Tabatabai, Svenja Höfmann, Tanja Zhou et al. Nov 03, 2025 pp. 3528-3528 10.1182/blood-2025-3528

Abstract Diffuse large B cell lymphoma (DLBCL) is the most prevalent lymphoid malignancy in adults and exhibits significant heterogeneity. H...

Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel

Yein Jeon, Xiancheng Wu, Christy Khouderchah et al. Nov 03, 2025 pp. 4147-4147 10.1182/blood-2025-4147

Abstract Background: Ciltacabtagene autoleucel (cilta-cel) achieves high rates of durable responses in multiple myeloma (MM) but has been as...

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Samanta Catueno, Olayinka Okeleji, David McCall et al. Nov 03, 2025 pp. 6950-6950 10.1182/blood-2025-6950

Abstract Background Children with HOX-driven acute leukemias, including KMT2A and NUP98 rearrangements (r), have dismal outcomes after relap...

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Gail Roboz, Eunice Wang, Amir Fathi et al. Nov 03, 2025 pp. 766-766 10.1182/blood-2025-766

Abstract Introduction: Nucleophosmin 1 mutations (NPM1-m) drive leukemogenesis in approximately 30% of acute myeloid leukemia (AML) cases. Z...

PIM2-dependent modulation of mitochondrial mass and function in multiple myeloma

Daniela Petrusca, Christopher Schorr, Joyce Hardwick et al. Nov 03, 2025 pp. 3254-3254 10.1182/blood-2025-3254

Abstract Multiple myeloma (MM) is a uncurable hematological malignancy of bone marrow resident plasma cells. The primary cause of treatment...

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Matthew McGuirk et al. Nov 03, 2025 pp. 173-173 10.1182/blood-2025-173

Abstract Background: Donor age is a recognized factor influencing outcomes after allogeneic hematopoietic cell transplantation (allo-HCT), w...

Relationship between changes in quality of life and social function and treatment response in patients with idiopathic multicentric castleman disease: A single-center observational longitudinal survey

Jia Chen, Lu Zhang, Jian Li Nov 03, 2025 pp. 8061-8061 10.1182/blood-2025-8061

Abstract The majority of multicentric Castleman disease (MCD) patients in China are idiopathic MCD (iMCD) with systemic manifestations. The...

Patient-driven insights in sickle cell disease: Results from a global survey informing public health strategies

Mariangela Pellegrini, Baba Inusa, Raffaella Colombatti et al. Nov 03, 2025 pp. 4441-4441 10.1182/blood-2025-4441

Abstract Introduction An effective public health strategy aimed at improving outcomes in Sickle Cell Disease (SCD) must...

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma

Arwa Bohra, Surendra Dasari, Moritz Binder et al. Nov 03, 2025 pp. 7477-7477 10.1182/blood-2025-7477

Abstract Introduction Surface proteins in cancer not only reflect tumor–microenvironment interactions but also serve as targets for diagnost...

The impact of a clinical trial communication training workshop on hematology-oncology Fellows' knowledge, attitudes and behaviors: A mixed-methods evaluation

Carma Bylund, Susan Eggly, Daphne Friedman et al. Nov 03, 2025 pp. 834-834 10.1182/blood-2025-834

Abstract Introduction: Cancer clinical trials (CCTs) are essential to advancing the treatment of blood cancers and providing access to high-...

Single-unit cord blood transplantation reduces the risk of relapse and improves leukemia-free survival compared to other donor sources in allo-HSCT for patients with high-risk acute myeloid leukemia

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno et al. Nov 03, 2025 pp. 591-591 10.1182/blood-2025-591

Abstract Background: Outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk acute myeloid leu...

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wróbel et al. Nov 03, 2025 pp. 3898-3898 10.1182/blood-2025-3898

Abstract Introduction: The AMPLIFY trial evaluated fixed-duration acalabrutinib + venetoclax ± obinutuzumab (AV/AVO) vs chemoimmunotherapy (C...

PET/CT parameters as predictors of early progression risk in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Stanislav Kamyshanov, Anastasia Semenova, Alexey Subbotin et al. Nov 03, 2025 pp. 7513-7513 10.1182/blood-2025-7513

Abstract Introduction In recent years, the treatment of multiple myeloma (MM) has undergone substantial evolution, resulting in improved ove...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page